Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects-Reference-Cited by-同舟云学术

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects

Published:2018-02-05 Issue:3 Volume:7 Page:186-196
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Asaumi Ryuta¹,Toshimoto Kota²,Tobe Yoshifusa¹,Hashizume Kenta³,Nunoya Ken-ichi¹,Imawaka Haruo¹,Lee Wooin⁴,Sugiyama Yuichi²

Affiliation:

1. Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co., Ltd.; Tsukuba Ibaraki Japan

2. Sugiyama Laboratory; RIKEN Innovation Center, RIKEN; Yokohama Kanagawa Japan

3. Drug Development Solutions Division, Sekisui Medical Co., Ltd.; Ibaraki Japan

4. College of Pharmacy and Research Institute of Pharmaceutical Sciences; Seoul National University; Seoul Korea

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Reference50 articles.

1. Clinical pharmacokinetics of rifampicin;Acocella;Clin. Pharmacokinet.,1978

2. Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over;Acocella;a period of two weeks. Chemotherapy,1971

3. Pharmacokinetic interactions with rifampicin:;Niemi;clinical relevance. Clin. Pharmacokinet.,2003

4. Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs;Maeda;Biol. Pharm. Bull.,2015

5. Predicting in vivo drug interactions from in vitro drug discovery data;Wienkers;Nat. Rev. Drug. Discov.,2005

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin;Clinical and Translational Science;2024-08

2. Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice;Drug Metabolism and Pharmacokinetics;2024-08

3. Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework;CPT: Pharmacometrics & Systems Pharmacology;2024-06-19

4. Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases;Scientific Reports;2024-06-03

5. Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models;Drug Metabolism and Pharmacokinetics;2024-06